Effects of famciclovir in cats with spontaneous acute upper respiratory tract disease

Lucy Kopecny, David J Maggs, Christian M. Leutenegger, Lynelle R Johnson

Research output: Contribution to journalArticle

Abstract

Objectives: The aim of this study was to assess the effects of famciclovir administration in cats with spontaneously acquired acute upper respiratory tract disease. Methods: Twenty-four kittens with clinical signs of acute upper respiratory tract disease were randomly allocated to receive doxycycline (5 mg/kg PO q12h) alone (group D; n = 12) or with famciclovir (90 mg/kg PO q12h; group DF; n = 12) for up to 3 weeks. Clinical disease severity was scored at study entry and daily thereafter. Oculo-oropharyngeal swabs collected at study entry and exit were assessed using quantitative PCR for nucleic acids of feline herpesvirus type 1 (FHV-1), feline calicivirus (FCV), Chlamydia felis, Bordetella bronchiseptica and Mycoplasma felis. Results: The median (range) age of cats was 1.5 (1–6) months in group D vs 1.6 (1–5) months in group DF (P = 0.54). Pathogens detected in oculo-oropharyngeal swabs at study entry included FCV (n = 13/24; 54%), M felis (n = 8/24; 33%), FHV-1 (n = 7/24; 29%), C felis (n = 7/24; 29%) and B bronchiseptica (n = 3/24; 12%). Median (range) duration of clinical signs was 11.5 (3–21) days in group DF and 11 (3–21) days in group D (P = 0.75). Median (range) total disease score at the end of the study did not differ between groups (group D 1 [1–1] vs group DF 1 [1–3]; P = 0.08). Conclusions and relevance: This study revealed no significant difference in response to therapy between cats treated with doxycycline alone or with famciclovir: cats improved rapidly in both groups. However, identification of FHV-1 DNA was relatively uncommon in this study and clinical trials focused on FHV-1-infected cats are warranted to better evaluate famciclovir efficacy.

Original languageEnglish (US)
JournalJournal of Feline Medicine and Surgery
DOIs
StatePublished - Jan 1 2019

Fingerprint

Respiratory Tract Diseases
Felis
Felid herpesvirus 1
respiratory tract diseases
Herpesviridae
Felidae
Cats
cats
Feline Calicivirus
Feline calicivirus
doxycycline
Doxycycline
Mycoplasma felis
Bordetella bronchiseptica
Chlamydia
kittens
Mycoplasma
disease severity
Nucleic Acids
nucleic acids

Keywords

  • doxycycline
  • famciclovir
  • Herpesvirus
  • quantitative PCR

ASJC Scopus subject areas

  • Small Animals

Cite this

Effects of famciclovir in cats with spontaneous acute upper respiratory tract disease. / Kopecny, Lucy; Maggs, David J; Leutenegger, Christian M.; Johnson, Lynelle R.

In: Journal of Feline Medicine and Surgery, 01.01.2019.

Research output: Contribution to journalArticle

@article{4ec616d639254caaa9741cc8cc531f49,
title = "Effects of famciclovir in cats with spontaneous acute upper respiratory tract disease",
abstract = "Objectives: The aim of this study was to assess the effects of famciclovir administration in cats with spontaneously acquired acute upper respiratory tract disease. Methods: Twenty-four kittens with clinical signs of acute upper respiratory tract disease were randomly allocated to receive doxycycline (5 mg/kg PO q12h) alone (group D; n = 12) or with famciclovir (90 mg/kg PO q12h; group DF; n = 12) for up to 3 weeks. Clinical disease severity was scored at study entry and daily thereafter. Oculo-oropharyngeal swabs collected at study entry and exit were assessed using quantitative PCR for nucleic acids of feline herpesvirus type 1 (FHV-1), feline calicivirus (FCV), Chlamydia felis, Bordetella bronchiseptica and Mycoplasma felis. Results: The median (range) age of cats was 1.5 (1–6) months in group D vs 1.6 (1–5) months in group DF (P = 0.54). Pathogens detected in oculo-oropharyngeal swabs at study entry included FCV (n = 13/24; 54{\%}), M felis (n = 8/24; 33{\%}), FHV-1 (n = 7/24; 29{\%}), C felis (n = 7/24; 29{\%}) and B bronchiseptica (n = 3/24; 12{\%}). Median (range) duration of clinical signs was 11.5 (3–21) days in group DF and 11 (3–21) days in group D (P = 0.75). Median (range) total disease score at the end of the study did not differ between groups (group D 1 [1–1] vs group DF 1 [1–3]; P = 0.08). Conclusions and relevance: This study revealed no significant difference in response to therapy between cats treated with doxycycline alone or with famciclovir: cats improved rapidly in both groups. However, identification of FHV-1 DNA was relatively uncommon in this study and clinical trials focused on FHV-1-infected cats are warranted to better evaluate famciclovir efficacy.",
keywords = "doxycycline, famciclovir, Herpesvirus, quantitative PCR",
author = "Lucy Kopecny and Maggs, {David J} and Leutenegger, {Christian M.} and Johnson, {Lynelle R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1098612X19857587",
language = "English (US)",
journal = "Journal of Feline Medicine and Surgery",
issn = "1098-612X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Effects of famciclovir in cats with spontaneous acute upper respiratory tract disease

AU - Kopecny, Lucy

AU - Maggs, David J

AU - Leutenegger, Christian M.

AU - Johnson, Lynelle R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: The aim of this study was to assess the effects of famciclovir administration in cats with spontaneously acquired acute upper respiratory tract disease. Methods: Twenty-four kittens with clinical signs of acute upper respiratory tract disease were randomly allocated to receive doxycycline (5 mg/kg PO q12h) alone (group D; n = 12) or with famciclovir (90 mg/kg PO q12h; group DF; n = 12) for up to 3 weeks. Clinical disease severity was scored at study entry and daily thereafter. Oculo-oropharyngeal swabs collected at study entry and exit were assessed using quantitative PCR for nucleic acids of feline herpesvirus type 1 (FHV-1), feline calicivirus (FCV), Chlamydia felis, Bordetella bronchiseptica and Mycoplasma felis. Results: The median (range) age of cats was 1.5 (1–6) months in group D vs 1.6 (1–5) months in group DF (P = 0.54). Pathogens detected in oculo-oropharyngeal swabs at study entry included FCV (n = 13/24; 54%), M felis (n = 8/24; 33%), FHV-1 (n = 7/24; 29%), C felis (n = 7/24; 29%) and B bronchiseptica (n = 3/24; 12%). Median (range) duration of clinical signs was 11.5 (3–21) days in group DF and 11 (3–21) days in group D (P = 0.75). Median (range) total disease score at the end of the study did not differ between groups (group D 1 [1–1] vs group DF 1 [1–3]; P = 0.08). Conclusions and relevance: This study revealed no significant difference in response to therapy between cats treated with doxycycline alone or with famciclovir: cats improved rapidly in both groups. However, identification of FHV-1 DNA was relatively uncommon in this study and clinical trials focused on FHV-1-infected cats are warranted to better evaluate famciclovir efficacy.

AB - Objectives: The aim of this study was to assess the effects of famciclovir administration in cats with spontaneously acquired acute upper respiratory tract disease. Methods: Twenty-four kittens with clinical signs of acute upper respiratory tract disease were randomly allocated to receive doxycycline (5 mg/kg PO q12h) alone (group D; n = 12) or with famciclovir (90 mg/kg PO q12h; group DF; n = 12) for up to 3 weeks. Clinical disease severity was scored at study entry and daily thereafter. Oculo-oropharyngeal swabs collected at study entry and exit were assessed using quantitative PCR for nucleic acids of feline herpesvirus type 1 (FHV-1), feline calicivirus (FCV), Chlamydia felis, Bordetella bronchiseptica and Mycoplasma felis. Results: The median (range) age of cats was 1.5 (1–6) months in group D vs 1.6 (1–5) months in group DF (P = 0.54). Pathogens detected in oculo-oropharyngeal swabs at study entry included FCV (n = 13/24; 54%), M felis (n = 8/24; 33%), FHV-1 (n = 7/24; 29%), C felis (n = 7/24; 29%) and B bronchiseptica (n = 3/24; 12%). Median (range) duration of clinical signs was 11.5 (3–21) days in group DF and 11 (3–21) days in group D (P = 0.75). Median (range) total disease score at the end of the study did not differ between groups (group D 1 [1–1] vs group DF 1 [1–3]; P = 0.08). Conclusions and relevance: This study revealed no significant difference in response to therapy between cats treated with doxycycline alone or with famciclovir: cats improved rapidly in both groups. However, identification of FHV-1 DNA was relatively uncommon in this study and clinical trials focused on FHV-1-infected cats are warranted to better evaluate famciclovir efficacy.

KW - doxycycline

KW - famciclovir

KW - Herpesvirus

KW - quantitative PCR

UR - http://www.scopus.com/inward/record.url?scp=85068329668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068329668&partnerID=8YFLogxK

U2 - 10.1177/1098612X19857587

DO - 10.1177/1098612X19857587

M3 - Article

AN - SCOPUS:85068329668

JO - Journal of Feline Medicine and Surgery

JF - Journal of Feline Medicine and Surgery

SN - 1098-612X

ER -